文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Functional Cure for Hepatitis B Virus: Challenges and Achievements.

作者信息

Shechter Oren, Sausen Daniel G, Dahari Harel, Vaillant Andrew, Cotler Scott J, Borenstein Ronen

机构信息

Eastern Virginia Medical School, Norfolk, VA 23501, USA.

Naval Medical Center Portsmouth, Portsmouth, VA 23708, USA.

出版信息

Int J Mol Sci. 2025 Apr 11;26(8):3633. doi: 10.3390/ijms26083633.


DOI:10.3390/ijms26083633
PMID:40332208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12026623/
Abstract

The Hepatitis B Virus (HBV) presents a formidable global health challenge, impacting hundreds of millions worldwide and imposing a considerable burden on healthcare systems. The elusive nature of the virus, with its ability to establish chronic infection and evade immune detection, and the absence of curative agents have prompted efforts to develop novel therapeutic approaches beyond current antiviral treatments. This review addresses the challenging concept of a functional cure for HBV, a state characterized by the suppression of HBV and HBsAg, mitigating disease progression and transmission without a complete cure. We provide an overview of HBV epidemiology and its clinical impact, followed by an exploration of the current treatment landscape and its limitations. The immunological basis of a functional cure is then discussed, exploring the intricate interplay between the virus and the host immune response. Emerging therapeutic approaches, such as RNA interference-based interventions, entry inhibitors, nucleic acid polymers, and therapeutic vaccines, are discussed with regard to their success in achieving a functional cure. Lastly, the review underscores the urgent need for innovative strategies to achieve a functional cure for HBV.

摘要

相似文献

[1]
Functional Cure for Hepatitis B Virus: Challenges and Achievements.

Int J Mol Sci. 2025-4-11

[2]
Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.

J Hepatol. 2024-12

[3]
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?

J Hepatol. 2022-6

[4]
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2.

J Hepatol. 2024-9

[5]
HBV cure: why, how, when?

Curr Opin Virol. 2016-7-19

[6]
Latest developments in the treatment of hepatitis B.

Minerva Gastroenterol Dietol. 2016-3

[7]
Prospects for Controlling Hepatitis B Globally.

Pathogens. 2024-3-29

[8]
Role of Biomarkers in Guiding Cure of Viral Hepatitis B.

Semin Liver Dis. 2020-2

[9]
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.

Viruses. 2022-3-22

[10]
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.

J Hepatol. 2018-6-29

本文引用的文献

[1]
Assessing the virological response to direct-acting antiviral therapies in the HBV cure programme.

Virology. 2025-4

[2]
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed.

Nat Rev Gastroenterol Hepatol. 2025-3

[3]
Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review.

Gastro Hep Adv. 2024-8-23

[4]
HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.

Antiviral Res. 2025-2

[5]
A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.

Nature. 2024-7

[6]
Prospects for Controlling Hepatitis B Globally.

Pathogens. 2024-3-29

[7]
WHO 2024 hepatitis B guidelines: an opportunity to transform care.

Lancet Gastroenterol Hepatol. 2024-6

[8]
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2.

J Hepatol. 2024-9

[9]
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.

JHEP Rep. 2023-12-30

[10]
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients.

Clin Mol Hepatol. 2024-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索